

May 17, 2004

To Whom It May Concern

Company: Taisho Pharmaceutical Co.,Ltd.  
Representative: Akira Uehara, President  
(First Section of TSE: Code 4535)  
Contact: Takashi Shibata, Manager  
Public Relations Section  
(Tel: 81-3-3985-1115)

**Notification regarding Purchase of the Company's Own Shares**  
(Purchase of its treasury stock pursuant to Article 210 of the Commercial Code of Japan)

Taisho Pharmaceutical announces that its Board of Directors Meeting held today resolved that purchase of its own shares pursuant to the provisions of Article 210 of the Commercial Code of Japan will be proposed at the 95th Ordinary General Meeting of Shareholders scheduled on June 29, 2004.

1. Purpose of purchase of the Company's own shares

- (1) To provide the Company's shareholders with a profit by raising our capital efficiency and reducing the number of outstanding shares of common stock
- (2) To enable flexible financial administration that responds to business expansion

2. Details of purchase

- (1) Type of share: Taisho per-value common stock
- (2) Amount of stock: 7,000,000 shares (upper limit)
- (3) Total value of stock: ¥16.0 billion (upper limit)

Notes:

The Company would carry out the market purchase of common stock upon approval at the 95th Ordinary General Meeting of Shareholders to be held on June 29, 2004 and end the purchase after the 96th Ordinary General Meeting of Shareholders to be closed.